For intravenous infusion only for the treatment of:

ENHERTU is a HER2-directed antibody and topoisomerase inhibitor conjugate indicated

- for adult patients with locally advanced or metastatic HER2-positive gastric or
- the neoadjuvant or adjuvant setting and have developed disease recurrence during

The recommended dosage of ENHERTU for gastric cancer is 6.4 mg/kg given as an

The recommended dosage of ENHERTU for breast cancer is 5.4 mg/kg given as an

RECENT MAJOR CHANGES

Indications and Usage (1.1) 05/2022
Dosage and Administration (2.2) 05/2022
Warnings and Precautions (5.1, 5.2, 5.3) 05/2022

INDICATIONS AND USAGE

ENHERTU is a HER2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of:

- adult patients with unrespectable or metastatic HER2-positive breast cancer who have received a prior anti-HER2-based regimen either:
  - in the metastatic setting, or
  - in the neoadjuvant or adjuvant setting and have developed disease recurrence during or within six months of completing therapy. (1.1)
- adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma who have received a prior trastuzumab-based regimen. (1.2)

DOSAGE AND ADMINISTRATION

- Do not substitute ENHERTU for or with trastuzumab or ado-trastuzumab emtansine. (2.2, 2.4)
- For intravenous infusion only. Do not administer as an intravenous push or bolus. DO NOT use Sodium Chloride Injection, USP. (2.4)
- Premedicate for prevention of chemotherapy-induced nausea and vomiting. (2.2)
- The recommended dosage of ENHERTU for breast cancer is 5.4 mg/kg given as an intravenous infusion once every 3 weeks (21-day cycle) until disease progression or unacceptable toxicity. (2.2, 2.3)
- The recommended dosage of ENHERTU for gastric cancer is 6.4 mg/kg given as an intravenous infusion once every 3 weeks (21-day cycle) until disease progression or unacceptable toxicity. (2.2, 2.3)

ADVERSE REACTIONS

The most common adverse reactions (≥20%), including laboratory abnormalities, in patients with:

- breast cancer were nausea, decreased white blood cell count, decreased hemoglobin, decreased neutrophil count, increased aspartate aminotransferase, fatigue, decreased lymphocyte count, vomiting, decreased platelet count, increased alanine aminotransferase, increased blood alkaline phosphatase, allopnea, constipation, hypokalemia, decreased appetite, diarrhea, musculoskeletal pain, increased transaminases, respiratory infection, headache, and abdominal pain. (6.1)
- gastric cancer were decreased hemoglobin, decreased white blood cell count, decreased neutrophil count, decreased lymphocyte count, decreased platelet count, nausea, decreased appetite, increased aspartate aminotransferase, fatigue, increased blood alkaline phosphatase, increased alanine aminotransferase, diarrhea, hypokalemia, vomiting, constipation, increased blood bilirubin, pyrexia, and allopnea. (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact Daiichi Sankyo, Inc. at 1-877-437-7763 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

USE IN SPECIFIC POPULATIONS

- Lactation: Advise not to breastfeed. (8.2)
- Females and Males of Reproductive Potential: Verify pregnancy status of females prior to initiation of ENHERTU. (8.3)

See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.

Revised: 05/2022

FULL PRESCRIBING INFORMATION: CONTENTS*

1 INDICATIONS AND USAGE
1.1 Metastatic Breast Cancer
1.2 Locally Advanced or Metastatic Gastric Cancer

2 DOSAGE AND ADMINISTRATION
2.1 Patient Selection for Locally Advanced or Metastatic Gastric Cancer
2.2 Recommended Dosage and Schedules
2.3 Dose Modifications
2.4 Preparation for Administration

3 DOSAGE FORMS AND STRENGTHS

4 CONTRAINDICATIONS
5 WARNINGS AND PRECAUTIONS
5.1 Interstitial Lung Disease/Pneumonitis
5.2 Neutropenia
5.3 Left Ventricular Dysfunction
5.4 Embryo-Fetal Toxicity

6 ADVERSE REACTIONS
6.1 Clinical Trials Experience
6.2 Immunogenicity

8 USE IN SPECIFIC POPULATIONS
8.1 Pregnancy
8.2 Lactation

8.3 Females and Males of Reproductive Potential
8.4 Pediatric Use
8.5 Geriatric Use
8.6 Renal Impairment
8.7 Hepatic Impairment

11 DESCRIPTION

12 CLINICAL PHARMACOLOGY
12.1 Mechanism of Action
12.2 Pharmacodynamics
12.3 Pharmacokinetics

13 NONCLINICAL TOXICOLOGY
13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

14 CLINICAL STUDIES
14.1 Metastatic Breast Cancer
14.2 Locally Advanced or Metastatic Gastric Cancer

15 REFERENCES

16 HOW SUPPLIED/STORAGE AND HANDLING
16.1 How Supplied/Storage
16.2 Special Handling

17 PATIENT COUNSELING INFORMATION

* Sections or subsections omitted from the full prescribing information are not listed.
FULL PRESCRIBING INFORMATION

WARNING: INTERSTITIAL LUNG DISEASE and EMBRYO-FETAL TOXICITY

- Interstitial Lung Disease (ILD) and pneumonitis, including fatal cases, have been reported with ENHERTU. Monitor for and promptly investigate signs and symptoms including cough, dyspnea, fever, and other new or worsening respiratory symptoms. Permanently discontinue ENHERTU in all patients with Grade 2 or higher ILD/pneumonitis. Advise patients of the risk and the need to immediately report symptoms [see Dosage and Administration (2.3), Warnings and Precautions (5.1)].
- Embryo-Fetal Toxicity: Exposure to ENHERTU during pregnancy can cause embryo-fetal harm. Advise patients of these risks and the need for effective contraception [see Warnings and Precautions (5.4), Use in Specific Populations (8.1, 8.3)].

1 INDICATIONS AND USAGE

1.1 Metastatic Breast Cancer

ENHERTU is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received a prior anti-HER2-based regimen either:
- in the metastatic setting, or
- in the neoadjuvant or adjuvant setting and have developed disease recurrence during or within six months of completing therapy.

1.2 Locally Advanced or Metastatic Gastric Cancer

ENHERTU is indicated for the treatment of adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen.

2 DOSAGE AND ADMINISTRATION

2.1 Patient Selection for Locally Advanced or Metastatic Gastric Cancer

Select patients with locally advanced or metastatic gastric cancer based on HER2 protein overexpression or HER2 gene amplification. Reassess HER2 status if it is feasible to obtain a new tumor specimen after prior trastuzumab-based therapy and before treatment with ENHERTU.

Information on FDA-approved tests for the detection of HER2 protein overexpression and HER2 gene amplification in gastric cancer is available at: http://www.fda.gov/CompanionDiagnostics.

2.2 Recommended Dosage and Schedules

Do not substitute ENHERTU for or with trastuzumab or ado-trastuzumab emtansine.

- First infusion: Administer infusion over 90 minutes. Subsequent infusions: Administer over 30 minutes if prior infusions were well tolerated.
- Slow or interrupt the infusion rate if the patient develops infusion-related symptoms. Permanently discontinue ENHERTU in case of severe infusion reactions.

2.3 Dose Modifications

Management of adverse reactions may require temporary interruption, dose reduction, or treatment discontinuation of ENHERTU as described in Tables 1 and 2.

Do not re-escalate the ENHERTU dose after a dose reduction is made.

If a planned dose is delayed or missed, administer as soon as possible; do not wait until the next planned cycle. Adjust the schedule of administration to maintain a 3-week interval between doses. Administer the infusion at the dose and rate the patient tolerated in the most recent infusion.

### Table 1: Dose Reduction Schedule

<table>
<thead>
<tr>
<th>Dose Reduction Schedule</th>
<th>Breast Cancer</th>
<th>Gastric Cancer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Recommended starting dose</td>
<td>5.4 mg/kg</td>
<td>6.4 mg/kg</td>
</tr>
<tr>
<td>First dose reduction</td>
<td>4.4 mg/kg</td>
<td>5.4 mg/kg</td>
</tr>
<tr>
<td>Second dose reduction</td>
<td>3.2 mg/kg</td>
<td>4.4 mg/kg</td>
</tr>
</tbody>
</table>

### Table 2: Dose Modifications for Adverse Reactions

<table>
<thead>
<tr>
<th>Adverse Reaction</th>
<th>Severity</th>
<th>Treatment Modification</th>
</tr>
</thead>
<tbody>
<tr>
<td>Interstitial Lung Disease (ILD)/Pneumonitis</td>
<td>Asymptomatic ILD/ pneumonitis (Grade 1)</td>
<td>Interrupt ENHERTU until resolved to Grade 0, then:</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• if resolved in 28 days or less from date of onset, maintain dose.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• if resolved in greater than 28 days from date of onset, reduce dose one level (see Table 1).</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• consider corticosteroid treatment as soon as ILD/pneumonitis is suspected (see Warnings and Precautions (5.1)).</td>
</tr>
<tr>
<td>Symptomatic ILD/ pneumonitis (Grade 2 or greater)</td>
<td></td>
<td>• Permanently discontinue ENHERTU.</td>
</tr>
<tr>
<td>Neutropenia</td>
<td>Grade 3 (less than 1.0 to 0.5 x 10^9/L)</td>
<td>Interrupt ENHERTU until resolved to Grade 2 or less.</td>
</tr>
<tr>
<td></td>
<td>Grade 4 (less than 0.5 x 10^9/L)</td>
<td>Interrupt ENHERTU until resolved to Grade 2 or less.</td>
</tr>
</tbody>
</table>

• Reduce dose by one level (see Table 1).

| Febrile Neutropenia | Absolute neutrophil count of less than 1.0 x 10^9/L and temperature greater than 38.5°C or a sustained temperature of 38°C or greater for more than one hour | Interrupt ENHERTU until resolved. |
|                    | • Reduce dose by one level (see Table 1). |

| Thrombocytopenia    | Grade 3 (platelets less than 50 to 25 x 10^9/L) | Interrupt ENHERTU until resolved to Grade 1 or less. |
| Thrombocytopenia    | Grade 4 (platelets less than 25 x 10^9/L) | Interrupt ENHERTU until resolved to Grade 1 or less. |
|                    | • Reduce dose by one level (see Table 1). |

| Left Ventricular Dysfunction | LVEF greater than 45% and absolute decrease from baseline is 10% to 20% | Continue treatment with ENHERTU. |
| LVEF 40% to 45% | And absolute decrease from baseline is less than 10% | • Continue treatment with ENHERTU. |
| LVEF 40% to 45% | And absolute decrease from baseline is 10% to 20% | • Repeat LVEF assessment within 3 weeks. |
| LVEF less than 40% or absolute decrease from baseline is greater than 20% | • Interrupt ENHERTU. |
| LVEF less than 40% or absolute decrease from baseline is greater than 20% | • Repeat LVEF assessment within 3 weeks. |
| Symptomatic congestive heart failure (CHF) | | • If LVEF has not recovered to within 10% from baseline, permanently discontinue ENHERTU. |
| Symptomatic congestive heart failure (CHF) | | • If LVEF recovers to within 10% from baseline, resume treatment with ENHERTU at the same dose. |
| Symptomatic congestive heart failure (CHF) | | • Permanently discontinue ENHERTU. |

Toxicity grades are in accordance with National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 (NCI CTCAE v5.0).

2.4 Preparation for Administration

In order to prevent medication errors, check the vial labels to ensure that the drug being prepared and administered is ENHERTU (fam-trastuzumab deruxtecan-nxki) and not trastuzumab or ado-trastuzumab emtansine.

Reconstitute and further dilute ENHERTU prior to intravenous infusion. Use appropriate aseptic technique.

ENHERTU (fam-trastuzumab deruxtecan-nxki) is a hazardous drug. Follow applicable special handling and disposal procedures.1
Reconstitution
• Reconstitute immediately before dilution.
• More than one vial may be needed for a full dose. Calculate the dose (mg), the total volume of reconstituted ENHERTU solution required, and the number of vial(s) of ENHERTU needed [see Dosage and Administration (2.2)].
• Reconstitute each 100 mg vial by using a sterile syringe to slowly inject 5 mL of Sterile Water for Injection, USP into each vial to obtain a final concentration of 20 mg/mL.
• Swirl the vial gently until completely dissolved. Do not shake.
• Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. The solution should be colorless and colorless to light yellow. Do not use if visible particles are observed or if the solution is cloudy or discolored.
• If not used immediately, store the reconstituted ENHERTU vials in a refrigerator at 2°C to 8°C (36°F to 46°F) for up to 24 hours from the time of reconstitution, protected from light. Do not freeze.
• The product does not contain a preservative. Discard unused ENHERTU after 24 hours refrigerated.

Dilution
• Dilute the calculated volume of reconstituted ENHERTU in an intravenous infusion bag containing 100 mL of 5% Dextrose Injection, USP. DO NOT use Sodium Chloride Injection, USP. ENHERTU is compatible with an infusion bag made of polyvinylchloride or polyolefin (copolymer of ethylene and propylenepolypropylene).
• Gently invert the infusion bag to thoroughly mix the solution. Do not shake.
• Cover the infusion bag to protect from light.
• If not used immediately, store at room temperature for up to 4 hours including preparation and infusion, or in a refrigerator at 2°C to 8°C (36°F to 46°F) for up to 24 hours, protected from light. Do not freeze.
• Discard any unused portion left in the vial.

Administration
• If the prepared infusion solution was stored refrigerated (2°C to 8°C [36°F to 46°F]), allow the solution to reach room temperature prior to administration. Cover the infusion bag to protect from light.
• Administer ENHERTU as an intravenous infusion only with an infusion set made of polyolefin or polybutadiene.
• Administer ENHERTU with a 0.20 or 0.22 micron in-line polymersulfone (PES) or polysulfone (PS) filter.
• Do NOT administer as an intravenous push or bolus.
• Cover the infusion bag to protect from light during administration.
• Do not mix ENHERTU with other drugs or administer other drugs through the same intravenous line.

3 DOSE FORMS AND STRENGTHS
For injection: 100 mg of fam-trastuzumab deruxtecan-nxki as a white to yellowish white lyophilized powder in a single-dose vial for reconstitution and further dilution

4 CONTRAINDICATIONS
None.

5 WARNINGS AND PRECAUTIONS
5.1 Intertitial Lung Disease/Pneumonitis
Severe, life-threatening, or fatal interstitial lung disease (ILD), including pneumonitis, can occur in patients treated with ENHERTU [see Adverse Reactions (6.1)]. Advise patients to immediately report cough, dyspnea, fever, and/or any new or worsening respiratory symptoms. Monitor patients for signs and symptoms of ILD. Promptly investigate evidence of ILD. Evaluate patients with suspected ILD by radiographic imaging. Consider consultation with a pulmonologist. For asymptomatic (Grade 1) ILD, consider corticosteroid treatment (e.g., ≤0.5 mg/kg/day prednisolone or equivalent). Withhold ENHERTU until recovery [see Dosage and Administration (2.3)]. In cases of symptomatic ILD (Grade 2 or greater), promptly initiate systemic corticosteroid treatment (e.g., ≥1 mg/kg/day prednisolone or equivalent) and continue for at least 14 days followed by gradual taper for at least 4 weeks. Permanently discontinue ENHERTU in patients who are diagnosed with symptomatic (Grade 2 or greater) ILD [see Dosage and Administration (2.3)].

Metastatic Breast Cancer
In clinical studies, of the 491 patients with unrespectable or metastatic HER2-positive breast cancer treated with ENHERTU 5.4 mg/kg, ILD occurred in 13% of patients. Fatal outcomes due to ILD and/or pneumonitis occurred in 1.4% of patients treated with ENHERTU. Median time to first onset was 5.5 months (range: 1.1 to 20.8).

Locally Advanced or Metastatic Gastric Cancer
In DESTINY-Gastric01, of the 125 patients with locally advanced or metastatic HER2-positive gastric or GEJ adenocarcinoma treated with ENHERTU 6.4 mg/kg, ILD occurred in 10% of patients. Median time to first onset was 2.8 months (range: 1.2 to 21.0).

5.2 Neutropenia
Severe neutropenia, including febrile neutropenia, can occur in patients treated with ENHERTU. Monitor complete blood counts prior to initiation of ENHERTU and prior to each dose, and as clinically indicated. Based on the severity of neutropenia, ENHERTU may require dose interruption or reduction [see Dosage and Administration (2.3)].

Metastatic Breast Cancer
In clinical studies, of the 491 patients with unrespectable or metastatic HER2-positive breast cancer who received ENHERTU 5.4 mg/kg, a decrease in neutrophil count was reported in 68% of patients. Eighteen percent had Grade 3 or 4 decrease in neutrophil count. Median time to first onset of decreased neutrophil count was 22 days (range: 6 to 664). Febrile neutropenia was reported in 1.2% of patients.

Locally Advanced or Metastatic Gastric Cancer
In DESTINY-Gastric01, of the 125 patients with locally advanced or metastatic HER2-positive gastric or GEJ adenocarcinoma treated with ENHERTU 6.4 mg/kg, a decrease in neutrophil count was reported in 72% of patients. Fifty-one percent had Grade 3 or 4 decreased neutrophil count. Median time to first onset of decreased neutrophil count was 16 days (range: 4 to 187). Febrile neutropenia was reported in 4.8% of patients.

5.3 Left Ventricular Dysfunction
Patients treated with ENHERTU may be at increased risk of developing left ventricular dysfunction. Left ventricular ejection fraction (LVEF) decrease has been observed with anti-HER2 therapies, including ENHERTU. Assess LVEF prior to initiation of ENHERTU and at regular intervals during treatment as clinically indicated. Manage LVEF decrease through treatment interruption. Permanently discontinue ENHERTU if LVEF of less than 40% or absolute decrease from baseline of greater than 20% is confirmed. Permanently discontinue ENHERTU in patients with symptomatic congestive heart failure (CHF) [see Dosage and Administration (2.3)].

Treatment with ENHERTU has not been studied in patients with a history of clinically significant cardiac disease or LVEF less than 50% prior to initiation of treatment.

Metastatic Breast Cancer
In the 491 patients with unrespectable or metastatic HER2-positive breast cancer who received ENHERTU 5.4 mg/kg, 13 cases (2.6%) of asymptomatic LVEF decrease were reported.

Locally Advanced or Metastatic Gastric Cancer
In DESTINY-Gastric01, of the 125 patients with locally advanced or metastatic HER2-positive gastric or GEJ adenocarcinoma treated with ENHERTU 6.4 mg/kg, no clinical adverse events of heart failure were reported; however, on echocardiography, 8% were found to have asymptomatic Grade 2 decrease in LVEF.

5.4 Embryo-Fetal Toxicity
Based on its mechanism of action, ENHERTU can cause fetal harm when administered to a pregnant woman. In postmarketing reports, use of a HER2-directed antibody during pregnancy resulted in cases of oligohydramnios manifesting as fetal pulmonary hypoplasia, skeletal abnormalities, and neonatal death. Based on its mechanism of action, the topoisomerase inhibitor component of ENHERTU, DXd, can also cause embryo-fetal harm when administered to a pregnant woman because it is genotoxic and targets actively dividing cells [see Use in Specific Populations (8.1), Clinical Pharmacology (12.1), Nonclinical Toxicology (13.1)]. Advise patients of the potential risks to a fetus.

Verify the pregnancy status of females of reproductive potential prior to the initiation of ENHERTU. Advise females of reproductive potential to use effective contraception during treatment and for at least 7 months following the last dose of ENHERTU. Advise male patients with female partners of reproductive potential to use effective contraception during treatment with ENHERTU and for at least 4 months after the last dose of ENHERTU [see Use in Specific Populations (8.1, 8.3)].

6 ADVERSE REACTIONS
The following clinically significant adverse reactions are described elsewhere in the labeling:
• Intertitial Lung Disease/Pneumonitis [see Warnings and Precautions (5.1)]
• Neutropenia [see Warnings and Precautions (5.2)]
• Left Ventricular Dysfunction [see Warnings and Precautions (5.3)]

6.1 Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Metastatic Breast Cancer
The pooled safety population for patients with metastatic breast cancer described in the WARNINGS AND PRECAUTIONS reflects exposure to ENHERTU at 5.4 mg/kg given as an intravenous infusion once every 3 weeks (21-day cycle) in 491 patients in DESTINY-Breast03, DESTINY-Breast01, and Study DS8201-A-J101. Among 491 patients who received ENHERTU, the median duration of treatment was 13 months (range: 0.7 to 37). In this pooled safety population, the most common (≥20%) adverse reactions, including laboratory abnormalities, were nausea (78%), decreased white blood cell count (74%), decreased hemoglobin (68%), decreased neutrophil count (68%), increased aspartate aminotransferase (58%), fatigue (57%), decreased lymphocyte count (56%), vomiting (50%), decreased platelet count (49%), increased alanine aminotransferase (48%), increased blood alkaline phosphatase (45%), alopecia (41%), constipation (35%), hypokalemia (33%), decreased appetite (32%), diarrhea (31%), musculoskeletal pain (28%), increased transaminases (27%), respiratory infection (24%), headache (21%), and abdominal pain (21%).

DESTINY-Breast03
The safety of ENHERTU was evaluated in 257 patients with unrespectable or metastatic HER2-positive breast cancer who received at least one dose of ENHERTU 5.4 mg/kg in DESTINY-Breast03 [see Clinical Studies (14.1)]. ENHERTU was administered by intravenous infusion once every three weeks. The median duration of treatment was 14 months (range: 0.7 to 30) for patients who received ENHERTU and 7 months (range: 0.7 to 25) for patients who received ado-trastuzumab emtansine.
Serious adverse reactions occurred in 19% of patients receiving ENHERTU. Serious adverse reactions in >1% of patients who received ENHERTU were vomiting, interstitial lung disease, pneumonia, pyrexia, and urinary tract infection. Fatalities due to adverse reactions occurred in 0.8% of patients including COVID-19 and sudden death (one patient each).

ENHERTU was permanently discontinued in 14% of patients, of which IILD/pneumonitis accounted for 8%. Dose interruptions due to adverse reactions occurred in 44% of patients treated with ENHERTU. The most frequent adverse reactions (>2%) associated with dose interruption were neutropenia, leukopenia, anemia, thrombocytopenia, pneumonia, nausea, fatigue, and IILD/pneumonitis. Dose reductions occurred in 21% of patients treated with ENHERTU. The most frequent adverse reactions (>2%) associated with dose reduction were nausea, neutropenia, and fatigue.

The most common (>20%) adverse reactions, including laboratory abnormalities, were nausea, decreased white blood cell count, decreased neutrophil count, increased aspartate aminotransferase, decreased hemoglobin, decreased lymphocyte count, increased alanine aminotransferase, decreased platelet count, fatigue, vomiting, increased blood alkaline phosphatase, alopecia, hypokalemia, constipation, musculoskeletal pain, diarrhea, decreased appetite, headache, respiratory infection, abdominal pain, increased blood bilirubin, and stomatitis.

Tables 3 and 4 summarize common adverse reactions and laboratory abnormalities observed in DESTINY-Breast03.

### Table 3: Common Adverse Reactions (≥10%) All Grades or ≥2% Grades 3-4) in Patients Treated with ENHERTU in DESTINY-Breast03

<table>
<thead>
<tr>
<th>Adverse Reactions</th>
<th>ENHERTU 5.4 mg/kg N=257</th>
<th>Ado-trastuzumab emtansine 3.6 mg/kg N=261</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Gastrointestinal Disorders</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nausea</td>
<td>76%</td>
<td>70%</td>
</tr>
<tr>
<td>Vomiting</td>
<td>49%</td>
<td>40%</td>
</tr>
<tr>
<td>Constipation</td>
<td>34%</td>
<td>20%</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>29%</td>
<td>7%</td>
</tr>
<tr>
<td>Abdominal pain&lt;sup&gt;a&lt;/sup&gt;</td>
<td>21%</td>
<td>8%</td>
</tr>
<tr>
<td>Stomatitis&lt;sup&gt;b&lt;/sup&gt;</td>
<td>20%</td>
<td>5%</td>
</tr>
<tr>
<td>Dyspepsia</td>
<td>11%</td>
<td>6%</td>
</tr>
<tr>
<td><strong>General Disorders and Administration Site Conditions</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fatigue&lt;sup&gt;c&lt;/sup&gt;</td>
<td>49%</td>
<td>35%</td>
</tr>
<tr>
<td><strong>Blood and Lymphatic System Disorders</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anemia&lt;sup&gt;d&lt;/sup&gt;</td>
<td>33%</td>
<td>17%</td>
</tr>
<tr>
<td>Alopecia&lt;sup&gt;e&lt;/sup&gt;</td>
<td>37%</td>
<td>31%</td>
</tr>
<tr>
<td><strong>Musculoskeletal and Connective Tissue Disorders</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Musculoskeletal pain&lt;sup&gt;f&lt;/sup&gt;</td>
<td>31%</td>
<td>25%</td>
</tr>
<tr>
<td><strong>Metabolism and Nutrition Disorders</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Decreased appetite</td>
<td>29%</td>
<td>17%</td>
</tr>
<tr>
<td>Decreased weight</td>
<td>17%</td>
<td>6%</td>
</tr>
<tr>
<td><strong>Respiratory, Thoracic and Mediastinal Disorders</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Respiratory infection&lt;sup&gt;g&lt;/sup&gt;</td>
<td>22%</td>
<td>12%</td>
</tr>
<tr>
<td>Epistaxis</td>
<td>11%</td>
<td>16%</td>
</tr>
<tr>
<td>Cough</td>
<td>11%</td>
<td>10%</td>
</tr>
<tr>
<td>Interstitial lung disease&lt;sup&gt;h&lt;/sup&gt;</td>
<td>11%</td>
<td>19%</td>
</tr>
<tr>
<td><strong>Nervous System Disorders</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Headache</td>
<td>22%</td>
<td>16%</td>
</tr>
<tr>
<td>Peripheral neuropathy&lt;sup&gt;i&lt;/sup&gt;</td>
<td>13%</td>
<td>14%</td>
</tr>
<tr>
<td>Dizziness</td>
<td>13%</td>
<td>8%</td>
</tr>
</tbody>
</table>

**Table 4: Selected Laboratory Abnormalities in Patients in DESTINY-Breast03**

<table>
<thead>
<tr>
<th>Laboratory Parameter</th>
<th>ENHERTU 5.4 mg/kg N=257</th>
<th>Ado-trastuzumab emtansine 3.6 mg/kg N=261</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Hematology</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Decreased white blood cell count</td>
<td>74%</td>
<td>24%</td>
</tr>
<tr>
<td>Decreased neutrophil count</td>
<td>70%</td>
<td>30%</td>
</tr>
<tr>
<td>Decreased hemoglobin</td>
<td>64%</td>
<td>38%</td>
</tr>
<tr>
<td>Decreased lymphocyte count</td>
<td>55%</td>
<td>23%</td>
</tr>
<tr>
<td>Decreased platelet count</td>
<td>52%</td>
<td>24%</td>
</tr>
<tr>
<td><strong>Chemistry</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Increased aspartate aminotransferase</td>
<td>67%</td>
<td>83%</td>
</tr>
<tr>
<td>Increased alanine aminotransferase</td>
<td>53%</td>
<td>67%</td>
</tr>
<tr>
<td>Increased blood alkaline phosphatase</td>
<td>49%</td>
<td>46%</td>
</tr>
<tr>
<td>Hypokalemia</td>
<td>35%</td>
<td>39%</td>
</tr>
<tr>
<td>Increased blood bilirubin</td>
<td>20%</td>
<td>14%</td>
</tr>
<tr>
<td>Increased blood creatinine</td>
<td>16%</td>
<td>8%</td>
</tr>
</tbody>
</table>

Percentages were calculated using patients with worsening laboratory values from baseline and the number of patients with both baseline and post-treatment measurements as the denominator.

Frequencies were based on NCI CTCAE v.5.0 grade-derived laboratory abnormalities.

**DESTINY-Breast01 and Study DS8201-A-J101**

The safety of ENHERTU was evaluated in a pooled analysis of 234 patients with unresectable or metastatic HER2-positive breast cancer who received at least one dose of ENHERTU 5.4 mg/kg in DESTINY-Breast01 and Study DS8201-A-J101 (NCT02564900) [see Clinical Studies (14.1)]. ENHERTU was administered by intravenous infusion once every three weeks. The median duration of treatment was 7 months (range: 0.7 to 31).

In the pooled 234 patients, the median age was 56 years (range: 28-96), 74% of patients were <65 years, 99.6% of patients were female, and the majority were White (51%) or Asian (42%). Patients had an Eastern Cooperative Oncology Group (ECOG) performance status of 0 (58%) or 1 (42%) at baseline. Ninety-four percent had visceral disease, 31% had bone metastases, and 13% had brain metastases.

Serious adverse reactions occurred in 20% of patients receiving ENHERTU. Serious adverse reactions in >1% of patients who received ENHERTU were interstitial lung disease, pneumonia, fever, vomiting, nausea, cellulitis, hypokalemia, and intestinal obstruction. Fatalities due to adverse reactions occurred in 4.3% of patients, including interstitial lung disease (2.6%), and the following events occurred in one patient each (0.4%): acute hepatic failure/acute kidney injury, general physical health deterioration, pneumonia, and hemorrhagic shock.

<sup>a</sup> Grouped term of abdominal pain includes PTs of abdominal pain, abdominal discomfort, lower abdominal pain, and upper abdominal pain.
<sup>b</sup> Grouped term of stomatitis includes PTs of stomatitis, aphthous ulcer, mouth ulceration, oral mucosa erosion, and oral mucosal erosion.
<sup>c</sup> Grouped term of fatigue includes PTs of fatigue, asthenia, malaise, and lethargy.
<sup>d</sup> Grouped term of anemia includes PTs of anemia, decreased hemoglobin, and decreased red blood cell count.
<sup>e</sup> This Grade 3 event was reported by the investigator. Per NCI CTCAE v.5.0, the highest NCI CTCAE grade for alopecia is Grade 2.
<sup>f</sup> Grouped term of musculoskeletal pain includes PTs of back pain, myalgia, pain in extremity, musculoskeletal pain, muscle spasm, bone pain, neck pain, musculoskeletal chest pain, and limb discomfort.
<sup>g</sup> Grouped term of respiratory infection includes PTs of respiratory tract infection, lower and upper respiratory tract infection, pneumonia, influenza, influenza-like illness, viral upper respiratory infection, bronchitis, and respiratory syncytial virus infection.
<sup>h</sup> Interstitial lung disease includes events that were adjudicated as IILD for ENHERTU: pneumonitis, interstitial lung disease, organizing pneumonia, pneumonia, and pulmonary mass. For ado-trastuzumab emtansine: pneumonitis, interstitial lung disease, organizing pneumonia, and pulmonary embolism.
<sup>i</sup> Grouped term of peripheral neuropathy includes PTs of peripheral neuropathy, peripheral sensory neuropathy, and paresthesia.

Other clinically relevant adverse reactions reported in less than 10% of patients in the ENHERTU-treated group were:
- Respiratory, Thoracic and Mediastinal Disorders: dyspnea (8%)
- Skin and Subcutaneous Tissue Disorders: pruritus (6%) and skin hyperpigmentation (6%) [grouped term includes PTs of skin hyperpigmentation, skin discoloration, and pigmentation disorder]
- Nervous System Disorders: dysgeusia (6%)
- Metabolism and Nutrition Disorders: dehydration (4.3%)
- Eye Disorders: blurred vision (3.5%)
- Cardiac Disorders: asymptomatic left ventricular ejection fraction decrease (2.7%) [see Warnings and Precautions (5.3)]
- Injury, Poisoning and Procedural Complications: infusion-related reactions (2.3%) [grouped term includes PTs of hypersensitivity and infusion-related reactions]
- Blood and Lymphatic System Disorders: tebrile neutropenia (0.8%)
ENHERTU was permanently discontinued in 9% of patients, of which ILD accounted for 6%. Dose interruptions due to adverse reactions occurred in 33% of patients treated with ENHERTU. The most frequent adverse reactions (>2%) associated with dose interruption were neutropenia, anemia, thrombocytopenia, leukopenia, upper respiratory tract infection, fatigue, nausea, and ILD. Dose reductions occurred in 18% of patients treated with ENHERTU. The most frequent adverse reactions (>2%) associated with dose reduction were fatigue, nausea, and neutropenia.

The most common (≥20%) adverse reactions, including laboratory abnormalities, were nausea, decreased white blood cell count, decreased hemoglobin, decreased neutrophil count, fatigue, vomiting, alopecia, increased aspartate aminotransferase, increased alanine aminotransferase, decreased platelet count, constipation, decreased appetite, diarrhea, hypokalemia, and cough.

Tables 5 and 6 summarize common adverse reactions and laboratory abnormalities observed in ENHERTU-treated patients.

### Table 5: Common Adverse Reactions (≥10% All Grades or ≥2% Grades 3 or 4) in Patients in DESTINY-Breast01 and Study DS8201-A-J101

<table>
<thead>
<tr>
<th>Adverse Reactions</th>
<th>NHERTU 5.4 mg/kg N=234</th>
<th>All Grades</th>
<th>Grades 3 or 4</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Gastrointestinal Disorders</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nausea</td>
<td>79</td>
<td>7</td>
<td></td>
</tr>
<tr>
<td>Vomiting</td>
<td>47</td>
<td>3.8</td>
<td></td>
</tr>
<tr>
<td>Constipation</td>
<td>35</td>
<td>0.9</td>
<td></td>
</tr>
<tr>
<td>Diarrhea</td>
<td>29</td>
<td>1.7</td>
<td></td>
</tr>
<tr>
<td>Abdominal paina</td>
<td>19</td>
<td>1.3</td>
<td></td>
</tr>
<tr>
<td>Stomatitisa</td>
<td>14</td>
<td>0.9</td>
<td></td>
</tr>
<tr>
<td>Dysepsia</td>
<td>12</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td><strong>Skin and Subcutaneous Tissue Disorders</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alopecia</td>
<td>46</td>
<td>0.4</td>
<td></td>
</tr>
<tr>
<td>Rash†</td>
<td>10</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td><strong>Metabolism and Nutrition Disorders</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Decreased appetite</td>
<td>32</td>
<td>1.3</td>
<td></td>
</tr>
<tr>
<td><strong>Blood and Lymphatic System Disorders</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anemiaa</td>
<td>31</td>
<td>7</td>
<td></td>
</tr>
<tr>
<td><strong>Respiratory, Thoracic and Mediastinal Disorders</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cough</td>
<td>20</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Dyspnea</td>
<td>13</td>
<td>1.3</td>
<td></td>
</tr>
<tr>
<td>Epistaxis</td>
<td>13</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Interstitial lung diseasea</td>
<td>9</td>
<td>2.6</td>
<td></td>
</tr>
<tr>
<td><strong>Nervous System Disorders</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Headachea</td>
<td>19</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Dizziness</td>
<td>10</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td><strong>Infections and Infestations</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Upper respiratory tract infection</td>
<td>15</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td><strong>Eye Disorders</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dry eye</td>
<td>11</td>
<td>0.4</td>
<td></td>
</tr>
</tbody>
</table>

Events were graded using NCI CTCAE version 4.03. N = number of patients exposed; PT = preferred term.
a Grouped term of abdominal pain includes PTs of abdominal discomfort, gastrointestinal pain, abdominal pain, lower abdominal pain, and upper abdominal pain.
b Grouped term of stomatitis includes PTs of stomatitis, aphthous ulcer, mouth ulceration, oral mucosa erosion, and oral mucosa blistering. One Grade 1 event of aphthous ulcer was not included in the summary of grouped term stomatitis (from DESTINY-Breast01).c

c Grouped term of fatigue includes PTs of fatigue and asthenia.
d This Grade 3 event was reported by the investigator. Per NCI CTCAE v.4.03, the highest NCI CTCAE grade for alopecia is Grade 2.
e Grouped term of rash includes PTs of rash, pustular rash, and maculo-papular rash.
f Grouped term of anemia includes PTs of anemia, decreased hematocrit, and decreased red blood cell count.
g Interstitial lung disease includes events that were adjudicated as ILD: pneumonitis, interstitial lung disease, respiratory failure, organizing pneumonia, acute respiratory failure, lung infiltration, lymphangitis, and alveolitis.
h All events had fatal outcomes (n=6).
i Grouped term of headache includes PTs of headache, sinus headache, and migraine.
j Grouped term of upper respiratory tract infection includes PTs of influenza, influenza-like illness, and upper respiratory tract infection.
k This Grade 4 event was reported by the investigator. Per NCI CTCAE v.4.03, the highest NCI CTCAE grade for dry eye is Grade 3.

### Table 6: Selected Laboratory Abnormalities in Patients with Unresectable or Metastatic HER2-positive Breast Cancer Treated with ENHERTU in DESTINY-Breast01 and Study DS8201-A-J101

<table>
<thead>
<tr>
<th>Laboratory Parameter</th>
<th>ENHERTU 5.4 mg/kg N=234</th>
<th>All Grades</th>
<th>Grades 3 or 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hematology</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Increased aspartate aminotransferase</td>
<td>41</td>
<td>0.9</td>
<td></td>
</tr>
<tr>
<td>Increased alanine aminotransferase</td>
<td>38</td>
<td>0.4</td>
<td></td>
</tr>
<tr>
<td>Hypokalemia</td>
<td>26</td>
<td>3</td>
<td></td>
</tr>
</tbody>
</table>

Percentages were calculated using patients with worsening laboratory values from baseline and the number of patients with both baseline and post-treatment measurements as the denominator.

Frequencies were based on NCI CTCAE v.4.03 grade-derived laboratory abnormalities.

### Table 7: Adverse Reactions in ≥10% All Grades or ≥2% Grades 3 or 4 of Patients Receiving ENHERTU in DESTINY-Gastric01

<table>
<thead>
<tr>
<th>Adverse Reactions</th>
<th>ENHERTU 6.4 mg/kg N=125</th>
<th>All Grades</th>
<th>Grades 3 or 4</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Gastrointestinal Disorders</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nausea</td>
<td>63</td>
<td>4.8</td>
<td>47</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>32</td>
<td>2.4</td>
<td>32</td>
</tr>
<tr>
<td>Vomiting</td>
<td>26</td>
<td>0</td>
<td>8</td>
</tr>
<tr>
<td>Constipation</td>
<td>24</td>
<td>0</td>
<td>23</td>
</tr>
<tr>
<td>Abdominal paina</td>
<td>14</td>
<td>0.8</td>
<td>15</td>
</tr>
<tr>
<td>Stomatitisa</td>
<td>11</td>
<td>1.6</td>
<td>4.8</td>
</tr>
<tr>
<td><strong>Metabolism and Nutrition Disorders</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Decreased appetite</td>
<td>60</td>
<td>17</td>
<td>45</td>
</tr>
<tr>
<td>Dehydration</td>
<td>6</td>
<td>2.4</td>
<td>3.2</td>
</tr>
</tbody>
</table>

(continued)
Table 7: Adverse Reactions in ≥10% All Grades or ≥2% Grades 3 or 4 of Patients Receiving ENHERTU in DESTINY-Gastric01

<table>
<thead>
<tr>
<th>Adverse Reactions</th>
<th>All Grades %</th>
<th>Grades 3 or 4 %</th>
<th>All Grades %</th>
<th>Grades 3 or 4 %</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Blood and Lymphatic System Disorders</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anemiaa</td>
<td>58</td>
<td>38</td>
<td>31</td>
<td>23</td>
</tr>
<tr>
<td>Febrile neutropenia</td>
<td>4.8</td>
<td>4.8</td>
<td>3.2</td>
<td>3.2</td>
</tr>
<tr>
<td><strong>General Disorders and Administration Site Conditions</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fatigueb</td>
<td>55</td>
<td>9</td>
<td>44</td>
<td>4.8</td>
</tr>
<tr>
<td>Pyrexia</td>
<td>24</td>
<td>0</td>
<td>16</td>
<td>0</td>
</tr>
<tr>
<td>Periipheral edema</td>
<td>10</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td><strong>Skin and Subcutaneous Tissue Disorders</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alopecia</td>
<td>22</td>
<td>0</td>
<td>15</td>
<td>0</td>
</tr>
<tr>
<td><strong>Respiratory, Thoracic and Mediastinal Disorders</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Intestinal lung diseaseb</td>
<td>10</td>
<td>2.4</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td><strong>Hepatobiliary Disorders</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Abnormal hepatic function</td>
<td>8</td>
<td>3.2</td>
<td>1.6</td>
<td>1.6</td>
</tr>
</tbody>
</table>

Events were graded using NCI CTCAE version 4.03. N = number of patients exposed; PT = preferred term.

a Grouped term of abdominal pain includes PTs of abdominal discomfort, gastrointestinal pain, abdominal pain, lower abdominal pain, and upper abdominal pain.

b Grouped term of stomatitis includes PTs of stomatitis, aphthous ulcer, mouth ulceration, oral mucosa erosion, and oral mucosal blistersing.

c Grouped term of anemia includes PTs of anemia, decreased hemoglobin, decreased red blood cell count, and decreased hematocrit.

d Grouped term of fatigue includes PTs of fatigue, asthenia, and malaise.

e Interstitial lung disease includes events that were adjudicated as ILD: pneumonitis, interstitial lung disease, respiratory failure, organizing pneumonia, acute respiratory failure, lung infiltration, lymphangitis, and alveolitis.

Other clinically relevant adverse reactions reported in less than 10% of patients were:
- Cardiac Disorders: asymptomatic left ventricular ejection fraction decrease (8%) [see Warnings and Precautions (5.3)]
- Infections and Infestations: pneumonia (6%)
- Injury, Poisoning, and Procedural Complications: infusion-related reactions (1.6%)

Table 8: Selected Laboratory Abnormalities Occurring in Patients Receiving ENHERTU in DESTINY-Gastric01

<table>
<thead>
<tr>
<th>Laboratory Parameter</th>
<th>ENHERTU 6.4 mg/kg N=125</th>
<th>Irinotecan or Paclitaxel N=62</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Hematology</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Decreased hemoglobin</td>
<td>75</td>
<td>38</td>
</tr>
<tr>
<td>Decreased white blood cell count</td>
<td>74</td>
<td>29</td>
</tr>
<tr>
<td>Decreased neutrophil count</td>
<td>72</td>
<td>51</td>
</tr>
<tr>
<td>Decreased lymphocyte count</td>
<td>70</td>
<td>28</td>
</tr>
<tr>
<td>Decreased platelet count</td>
<td>68</td>
<td>12</td>
</tr>
<tr>
<td><strong>Chemistry</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Increased aspartate aminotransferase</td>
<td>58</td>
<td>9</td>
</tr>
<tr>
<td>Increased blood alkaline phosphatase</td>
<td>54</td>
<td>8</td>
</tr>
<tr>
<td>Increased alanine aminotransferase</td>
<td>47</td>
<td>9</td>
</tr>
<tr>
<td>Hypokalemia</td>
<td>30</td>
<td>4.8</td>
</tr>
<tr>
<td>Increased blood bilirubin</td>
<td>24</td>
<td>7</td>
</tr>
</tbody>
</table>

Percentages were calculated using patients with worsening laboratory values from baseline and the number of patients with both baseline and post-treatment measurements as the denominator.

Frequencies were based on NCI CTCAE v.4.03 grade-derived laboratory abnormalities.

6.2 Immunogenicity
As with all therapeutic proteins, there is a potential for immunogenicity. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparisons of the incidence of antibodies to ENHERTU in the studies described below with the incidence of antibodies in other studies or to other products may be misleading.

Treatmement-emergent anti-fam-trastuzumab deruxtecan-nxki antibodies (ADA) developed in 2.1% (27/1311) patients who received ENHERTU across all doses. The incidence of neutralizing antibodies against fam-trastuzumab deruxtecan-nxki was 0.1% (1/1311). Due to the limited number of patients who tested positive for ADA, no conclusions can be drawn concerning a potential effect of immunogenicity on efficacy or safety.

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Risk Summary
Based on its mechanism of action, ENHERTU can cause fetal harm when administered to a pregnant woman. There are no available data on the use of ENHERTU in pregnant women. In postmarketing reports, use of a HER2-directed antibody during pregnancy resulted in cases of oligohydramnios manifesting as fetal pulmonary hypoplasia, skeletal abnormalities, and neonatal death (see Data). Based on its mechanism of action, the topoisomerase inhibitor component of ENHERTU, DXd, can also cause embryo-fetal harm when administered to a pregnant woman because it is genotoxic and targets actively dividing cells [see Clinical Pharmacology (12.1), Nonclinical Toxicology (13.1)]. Advise patients of the potential risks to a fetus.

There are clinical considerations if ENHERTU is used in pregnant women, or if a patient becomes pregnant within 7 months following the last dose of ENHERTU (see Clinical Considerations).

The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.

Clinical Considerations
Fetal/Neonatal Adverse Reactions
Monitor women who received ENHERTU during pregnancy or within 7 months prior to conception for oligohydramnios. If oligohydramnios occurs, perform fetal testing that is appropriate for gestational age and consistent with community standards of care.

Data
Human Data
There are no available data on the use of ENHERTU in pregnant women. In postmarketing reports in pregnant women receiving a HER2-directed antibody, cases of oligohydramnios manifesting as fetal pulmonary hypoplasia, skeletal abnormalities, and neonatal death have been reported. These case reports described oligohydramnios in pregnant women who received a HER2-directed antibody either alone or in combination with chemotherapy. In some case reports, amniotic fluid index increased after use of a HER2-directed antibody was stopped.

Animal Data
There were no animal reproductive or developmental toxicity studies conducted with fam-trastuzumab deruxtecan-nxki.

8.2 Lactation

Risk Summary
There is no data regarding the presence of fam-trastuzumab deruxtecan-nxki in human milk, the effects on the breastfed child, or the effects on milk production. Because of the potential for serious adverse reactions in a breastfed child, advise women not to breastfeed during treatment with ENHERTU and for 7 months after the last dose.

8.3 Females and Males of Reproductive Potential

Pregnancy Testing
Verify pregnancy status of females of reproductive potential prior to initiation of ENHERTU.

Contraception
- Females
ENHERTU can cause fetal harm when administered to a pregnant woman [see Use in Specific Populations (8.1)]. Advise female patients of reproductive potential to use effective contraception during treatment with ENHERTU and for at least 7 months following the last dose.

- Males
Because of the potential for genotoxicity, advise male patients with female partners of reproductive potential to use effective contraception during treatment with ENHERTU and for at least 4 months following the last dose [see Nonclinical Toxicology (13.1)].

Infertility
Based on findings in animal toxicity studies, ENHERTU may impair male reproductive function and fertility [see Nonclinical Toxicology (13.1)].

8.4 Pediatric Use
Safety and effectiveness of ENHERTU have not been established in pediatric patients.

8.5 Geriatric Use
Of the 491 patients with HER2-positive breast cancer treated with ENHERTU 5.4 mg/kg, 22% were 65 years or older and 4% were 75 years or older. No overall differences in efficacy within clinical studies were observed between patients ≥65 years of age compared to younger patients. There was a higher incidence of Grade 3-4 adverse
At the recommended dosage of ENHERTU for patients with HER2-positive breast cancer, the geometric mean $C_{\text{max}}$ of fam-trastuzumab deruxtecan-nxki and DXd were 126 μg/mL (18%) and 5.2 ng/mL (42%), respectively, and the AUC_{0-17 days} of fam-trastuzumab deruxtecan-nxki and DXd were 743 μg·day/mL (26%) and 33 ng·day/mL (43%), respectively, based on population pharmacokinetic analysis. Accumulation of fam-trastuzumab deruxtecan-nxki was approximately 35% at steady-state (Cycle 3).

Locally Advanced or Metastatic Gastric Cancer

At the recommended dosage of ENHERTU for patients with HER2-positive gastric cancer, the geometric mean $C_{\text{max}}$ of fam-trastuzumab deruxtecan-nxki and DXd were 126 μg/mL (18%) and 5.2 ng/mL (42%), respectively, and the AUC_{0-17 days} of fam-trastuzumab deruxtecan-nxki and DXd were 743 μg·day/mL (26%) and 33 ng·day/mL (43%), respectively, based on population pharmacokinetic analysis. Accumulation of fam-trastuzumab deruxtecan-nxki was approximately 35% at steady-state (Cycle 3).

Distribution

Based on population pharmacokinetic analysis, the estimated volume of distribution of the central compartment ($V_d$) of fam-trastuzumab deruxtecan-nxki was 2.71 L. For humans, DXd plasma protein binding is approximately 97% and the blood-to-plasma ratio is approximately 0.6, in vitro.

Elimination

The median elimination half-life ($t_{1/2}$) of fam-trastuzumab deruxtecan-nxki in patients with HER2-positive metastatic breast cancer and gastric cancer was approximately 5.7-5.8 days. Based on population pharmacokinetic analysis, the estimated systemic clearance of fam-trastuzumab deruxtecan-nxki was 0.42 L/day. The median apparent elimination half-life ($t_{1/2}$) of DXd in patients with HER2-positive metastatic breast cancer and gastric cancer was approximately 5.5-6.8 days. Based on population pharmacokinetic analysis, the estimated apparent systemic clearance of DXd was 19.4 L/h.

Metabolism

The humanized HER2 IgG1 monoclonal antibody is expected to be degraded into small peptides and amino acids via catabolic pathways in the same manner as endogenous IgG.

In vitro, DXd is primarily metabolized by CYP3A4.

Specific Populations

No clinically significant differences in the pharmacokinetics of fam-trastuzumab deruxtecan-nxki or DXd were observed for age (20-96 years), race (Asian [n=759], White [n=449], Black or African American [n=30] and Other [n=69]), sex, body weight (27.3-125.4 kg), mild (total bilirubin $\leq$ ULN and any AST $>ULN$ or total bilirubin $>1$ to 1.5 times ULN and any AST) or moderate (total bilirubin $>1.5$ to 3 times ULN and any AST) hepatic impairment. In patients with moderate hepatic impairment, due to potentially increased exposure, closely monitor for increased toxicities related to the topoisomerase inhibitor, DXd [see Dosage and Administration (2.3)]. No data are available in patients with severe (total bilirubin $>3$ to 10 times ULN and any AST) hepatic impairment [see Clinical Pharmacology (12.3)].
14 CLINICAL STUDIES

14.1 Metastatic Breast Cancer

DESTINY-Breast03

The efficacy of ENHERTU was evaluated in study DESTINY-Breast03 (NCT03529110), a multicenter, open-label, randomized trial that enrolled 524 patients with HER2-positive, unresectable and/or metastatic breast cancer who received prior trastuzumab and taxane therapy for metastatic disease or developed disease recurrence during or within 6 months of completing adjuvant therapy. HER2 expression was based on archival tissue tested at a central laboratory prior to enrollment with HER2 positivity defined as HER2 IHC 3+ or ISH positive. Patients were excluded for a history of ILD/pneumonitis requiring treatment with steroids, ILD/pneumonitis at screening, or clinically significant cardiac disease. Patients were also excluded for untreated and symptomatic brain metastases. ECOG performance status >1, or prior treatment with an anti-HER2 antibody-drug conjugate in the metastatic setting.

Patients were randomized 1:1 to receive either ENHERTU 5.4 mg/kg (N=261) or ado-trastuzumab emtansine 3.6 mg/kg (N=263) by intravenous infusion every 3 weeks until unacceptable toxicity or disease progression. Randomization was stratified by hormone receptor status, prior treatment with pertuzumab, and visceral versus non-visceral disease. Tumor imaging was obtained every 6 weeks and CT/MRI of the brain was mandatory for all patients at baseline. The major efficacy outcomes were progression-free survival (PFS) as assessed by blinded independent central review (BICR) based on Response Evaluation Criteria in Solid Tumors (RECIST) v.1.1 and overall survival (OS). Confirmed objective response rate (ORR) was an additional outcome measure.

The median age was 54 years (range: 20-83); 80% were <65 years and 99.6% were female. The majority of patients were Asian (60%), White (27%) and Black (3.6%). Eleven percent (11%) of patients were of Hispanic/Latino ethnicity. Patients had an ECOG performance status of 0 (83%) or 1 (37%) at baseline. Seventy-three percent had visceral disease, 16% had brain metastases at baseline, 52% were hormone receptor positive and 48% of patients had received one line of prior systemic therapy in the metastatic setting. The percentage of patients who had not received prior treatment for metastatic disease was 10%.

Efficacy results are summarized in Table 9 and Figure 1. At the time of the PFS analysis, 16% of patients had died and overall survival (OS) was immature.

Table 9: Efficacy Results in DESTINY-Breast03

<table>
<thead>
<tr>
<th>Efficacy Parameter</th>
<th>ENHERTU 5.4 mg/kg</th>
<th>A do-trastuzumab emtansine 3.6 mg/kg</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>261</td>
<td>263</td>
</tr>
<tr>
<td>Number of events (%)</td>
<td>87 (33.3)</td>
<td>158 (60.1)</td>
</tr>
<tr>
<td>Median, months (95% CI)</td>
<td>(18.5, NE)</td>
<td>6.8 (5.6, 8.2)</td>
</tr>
<tr>
<td>Hazard ratio (95% CI)</td>
<td>0.28 (0.22, 0.37)</td>
<td>p-value: p&lt;0.0001</td>
</tr>
</tbody>
</table>

**Confirmed Objective Response Rate (ORR) per BICR**

- **N**: 248, 241
- **ORR (%)**: 205 (82.7), 87 (36.1)
- **95% CI**: (77.4, 87.2), (30.0, 42.5)
- **Complete Response n (%)**: 39 (15.7), 20 (8.3)
- **Partial Response n (%)**: 166 (66.9), 67 (27.8)

Cl = confidence interval; NR = not reached; NE=not estimable

*Analysis was performed based on the patients with measurable disease assessed by BICR at baseline.

Figure 1: Kaplan-Meier Plot of Progression-Free Survival per BICR (Intent-to-Treat Analysis Set)

DESTINY-Breast01

The efficacy of ENHERTU was evaluated in study DESTINY-Breast01 (NCT03248492), a multicenter, single-arm, trial that enrolled 184 female patients with HER2-positive, unresectable and/or metastatic breast cancer who had received two or more prior anti-HER2 therapies. Patients were excluded for a history of treated ILD or current ILD at screening. Patients were also excluded for history of clinically significant cardiac disease, active brain metastases, and ECOG performance status <1. HER2 expression was based on archival tissue tested at a central laboratory prior to enrollment with HER2 positivity defined as HER2 IHC 3+ or ISH positive.

Patients received ENHERTU 5.4 mg/kg by intravenous infusion every 3 weeks until unacceptable toxicity or disease progression. Tumor imaging was obtained every 6 weeks and CT/MRI of the brain was mandatory for patients with brain metastases at baseline. The major efficacy outcomes were confirmed objective response rate (ORR) assessed by independent central review (ICR) using RECIST v.1.1 and duration of response (DOR).

The median age was 55 years (range: 28-96); 76% of patients were <65 years. All 184 patients were female, and the majority were White (55%) or Asian (38%). Patients had an ECOG performance status of 0 (55%) or 1 (44%) at baseline. Ninety-two percent had visceral disease, 29% had bone metastases, and 13% had brain metastases. Fifty-three percent were hormone receptor positive. Sum of diameters of target lesions was ≤5 cm in 42%, and ≤5 cm in 50% (not evaluable by central review in 8% of patients).

The median number of prior cancer regimens in the locally advanced/metastatic setting was 5 (range: 2-17). All patients received prior trastuzumab, ado-trastuzumab emtansine, and 66% had prior pertuzumab.

Efficacy results are summarized in Table 10.

Table 10: Efficacy Results by Independent Central Review in DESTINY-Breast01

<table>
<thead>
<tr>
<th>Efficacy Parameter</th>
<th>DESTINY-Breast01 N=184</th>
</tr>
</thead>
<tbody>
<tr>
<td>Confirmed Objective Response Rate (ORR) (95% Cl) †</td>
<td>60.3% (52.9, 67.4)</td>
</tr>
<tr>
<td>Complete Response</td>
<td>4.3%</td>
</tr>
<tr>
<td>Partial Response</td>
<td>56.0%</td>
</tr>
<tr>
<td>Duration of Response* (Median, months (95% Cl) †)</td>
<td>14.8 (13.8, 16.9)</td>
</tr>
</tbody>
</table>

ORR 95% CI calculated using Clopper-Pearson method

* DOR is based on median duration of follow-up of 11.1 months.

†Median DOR based on Kaplan-Meier estimate; 95% CI calculated using Brookmeyer-Crowley method

14.2 Locally Advanced or Metastatic Gastric Cancer

The efficacy of ENHERTU was evaluated in study DESTINY-Gastric01 (NCT03329690), a multicenter, open-label, randomized trial conducted in Japan and South Korea that enrolled 188 adult patients with HER2-positive (IHC 3+ or IHC 2+/ISH positive), locally advanced or metastatic gastric or GEJ adenocarcinoma who had progressed on at least two prior regimens including trastuzumab, a fluoropyrimidine- and a platinum-containing chemotherapy. HER2 expression was determined by a central lab on tissue obtained either before or after prior trastuzumab treatment. Patients were excluded for a history of treated or current ILD, a history of clinically significant cardiac disease, active brain metastases, or ECOG performance status >1.

Patients were randomized 2:1 to receive ENHERTU (N=126) 6.4 mg/kg intravenously every 3 weeks or physician’s choice of chemotherapy: irinotecan monotherapy (N=55) or paclitaxel monotherapy (N=7) 80 mg/m2 every 3 weeks or paclitaxel monotherapy: irinotecan monotherapy (N=55) 150 mg/m2 intravenously every 2 weeks or paclitaxel monotherapy (N=7) 80 mg/m2 intravenously every 3 weeks. Randomization was stratified by HER2 status (IHC 3+ or IHC 2+/ISH+), ECOG performance status (0 or 1), and region (Japan or South Korea).

Efficacy assessments were performed at screening and every 6 weeks from the first treatment dose. Treatment was administered until unacceptable toxicity or disease progression. The major efficacy outcomes were ORR assessed by ICR according to RECIST v.1.1 and OS in the intent-to-treat population. Additional efficacy outcomes were PFS and DOR.

The median age was 66 years (range 28 to 82); 76% were male; and 100% were Asian. All patients received a trastuzumab product. Patients had an ECOG performance status of either 0 (49%) or 1 (51%); 87% had gastric adenocarcinoma and 13% had GEJ adenocarcinoma; 76% were IHC 3+ and 23% were IHC 2+/ISH+, 66% had inoperable advanced cancer; 35% had postoperative recurrent cancer; 54% had liver metastases; 29% had lung metastases; 45% had three or more prior regimens in the locally advanced or metastatic setting. A total of 30% of patients were identified as HER2-positive using tissue obtained following prior treatment with a trastuzumab product.

Efficacy results are summarized in Table 11, and the Kaplan-Meier curve for OS is shown in Figure 2.
Table 11: Efficacy Results in DESTINY-Gastric01

<table>
<thead>
<tr>
<th>Efficacy Parameter</th>
<th>ENHERTU N=126</th>
<th>Irinotecan or Paclitaxel N=62</th>
</tr>
</thead>
<tbody>
<tr>
<td>Overall Survival (OS)*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median, months (95% CI)†</td>
<td>12.5 (9.6, 14.3)</td>
<td>8.4 (6.9,10.7)</td>
</tr>
<tr>
<td>Hazard ratio (95% CI)‡</td>
<td>0.59 (0.39, 0.88)</td>
<td></td>
</tr>
<tr>
<td>p-value§</td>
<td>0.0097</td>
<td></td>
</tr>
<tr>
<td>Progression-Free Survival (PFS)§</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median, months (95% CI)†</td>
<td>5.6 (4.3, 6.9)</td>
<td>3.5 (2.0, 4.3)</td>
</tr>
<tr>
<td>Hazard ratio (95% CI)‡</td>
<td>0.47 (0.31, 0.71)</td>
<td></td>
</tr>
<tr>
<td>Confirmed Objective Response Rate (ORR)§</td>
<td></td>
<td></td>
</tr>
<tr>
<td>n (%)</td>
<td>51 (40.5)</td>
<td>7 (11.3)</td>
</tr>
<tr>
<td>95% CI¶</td>
<td>(31.8, 49.6)</td>
<td>(4.7, 21.9)</td>
</tr>
<tr>
<td>p-value#</td>
<td>&lt;0.0001</td>
<td></td>
</tr>
<tr>
<td>Complete Response n (%)</td>
<td>10 (7.9)</td>
<td>0 (0.0)</td>
</tr>
<tr>
<td>Partial Response n (%)</td>
<td>41 (32.5)</td>
<td>7 (11.3)</td>
</tr>
<tr>
<td>Duration of Response (DOR)§</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median, months (95% CI)†</td>
<td>11.3 (5.6, NR)</td>
<td>3.9 (3.0, 4.9)</td>
</tr>
</tbody>
</table>

CI = confidence interval; NR = not reached
*OS was evaluated following a statistically significant outcome of ORR.
†Median based on Kaplan-Meier estimate; 95% CI for median calculated using Brookmeyer-Crowley method
‡Based on the stratified Cox proportional hazards regression model (stratified by region)
§Based on the stratified log-rank test (stratified by region)
¶95% exact binomial confidence interval
#Based on the stratified Cochran-Mantel-Haenszel test (stratified by region)

Figure 2: Kaplan-Meier Plot of Overall Survival

Store vials in a refrigerator at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light until time of reconstitution. Do not freeze. Do not shake the reconstituted or diluted solution [see Dosage and Administration (2.4)].

16.2 Special Handling
ENHERTU (fam-trastuzumab deruxtecan-nxki) is a hazardous drug. Follow applicable special handling and disposal procedures.1

17 PATIENT COUNSELING INFORMATION
Advise the patient to read the FDA-approved patient labeling (Medication Guide).

Interstitial Lung Disease
• Inform patients of the risks of severe or fatal ILD. Advise patients to contact their healthcare provider immediately for any of the following: cough, shortness of breath, fever, or other new or worsening respiratory symptoms [see Warnings and Precautions (5.1)].

Neutropenia
• Advise patients of the possibility of developing neutropenia and to immediately contact their healthcare provider should they develop a fever, particularly in association with any signs of infection [see Warnings and Precautions (5.2)].

Left Ventricular Dysfunction
• Advise patients to contact their healthcare provider immediately for any of the following: new onset or worsening shortness of breath, cough, fatigue, swelling of ankles/legs, palpitations, sudden weight gain, dizziness, loss of consciousness [see Warnings and Precautions (5.3)].

Embryo-Fetal Toxicity
• Inform female patients of the potential risk to a fetus. Advise female patients to contact their healthcare provider of a known or suspected pregnancy [see Warnings and Precautions (5.4), Use in Specific Populations (8.1)].

• Advise females of reproductive potential to use effective contraception during treatment with ENHERTU and for at least 7 months after the last dose [see Use in Specific Populations (8.3)].

• Advise male patients with female partners of reproductive potential to use effective contraception during treatment with ENHERTU and for at least 4 months after the last dose [see Use in Specific Populations (8.3)].

Lactation
• Advise women not to breastfeed during treatment and for 7 months after the last dose of ENHERTU [see Use in Specific Populations (8.2)].

Infertility
• Advise males of reproductive potential that ENHERTU may impair fertility [see Use in Specific Populations (8.3)].

Manufactured by:
Daiichi Sankyo, Inc., Basking Ridge, NJ 07920
U.S. License No. 2128
Marketed by:
Daiichi Sankyo, Inc., Basking Ridge, NJ 07920 and AstraZeneca Pharmaceuticals LP, Wilmington, DE 19850
ENHERTU® is a registered trademark of Daiichi Sankyo Company, Ltd. © 2022 Daiichi Sankyo Co., Ltd.
USPI-ENH-C8-0522-r003
What is the most important information I should know about ENHERTU?

ENHERTU can cause serious side effects, including:

- Lung problems that may be severe, life-threatening or that may lead to death. If you develop lung problems your healthcare provider may treat you with corticosteroid medicines. Tell your healthcare provider right away if you get any of the following signs and symptoms:
  - cough
  - trouble breathing or shortness of breath
  - fever
  - other new or worsening breathing symptoms (e.g., chest tightness, wheezing)

- Low white blood cell count (neutropenia). Low white blood cell counts are common with ENHERTU and can sometimes be severe. Your healthcare provider will check your white blood cell counts before starting ENHERTU and before starting each dose. Tell your healthcare provider right away if you develop any signs or symptoms of an infection or have fever or chills during treatment with ENHERTU.

- Heart problems that may affect your heart’s ability to pump blood. Your healthcare provider will check your heart function before starting treatment with ENHERTU. Tell your healthcare provider right away if you get any of the following signs and symptoms:
  - new or worsening shortness of breath
  - irregular heartbeat
  - sudden weight gain
  - coughing
  - dizziness or feeling light-headed
  - feeling tired
  - swelling of your ankles or legs
  - loss of consciousness

Your healthcare provider will check you for these side effects during your treatment with ENHERTU. Your healthcare provider may reduce your dose, delay treatment or completely stop treatment with ENHERTU if you have severe side effects.

- Damage to your liver. Your liver may become inflamed or damaged during your treatment with ENHERTU. This is called liver damage or liver failure. Your healthcare provider will check your liver function before starting ENHERTU and before starting each dose. Tell your healthcare provider right away if you get any of the following signs and symptoms:
  - nausea
  - low white blood cell counts
  - low red blood cell counts
  - increased liver function tests
  - feeling tired
  - vomiting
  - low platelet counts
  - hair loss

- Low white blood cell counts. Low white blood cell counts are common with ENHERTU and can sometimes be severe. Your healthcare provider will check your white blood cell counts before starting ENHERTU and before starting each dose. Tell your healthcare provider right away if you develop any signs or symptoms of an infection or have fever or chills during treatment with ENHERTU.

- Other new or worsening symptoms include:
  - nausea
  - diarrhea
  - vomiting
  - constipation
  - low levels of blood potassium
  - decreased appetite
  - constipation
  - fever
  - hair loss
  - increased liver function tests
  - feeling tired

See “What are the possible side effects of ENHERTU?” for more information about side effects.

What is ENHERTU?

ENHERTU is a prescription medicine used in adults to treat human epidermal growth factor receptor 2 (HER2)-positive:
- breast cancer that cannot be removed by surgery or that has spread to other parts of the body (metastatic), and who have received a prior anti-HER2 breast cancer treatment:
  - for metastatic disease, or
  - have breast cancer that has come back during or within 6 months of completing treatment for their early-stage breast cancer.
- stomach cancer called gastric or gastroesophageal junction (GEJ) adenocarcinoma that has spread to areas near your stomach (locally advanced) or that has spread to other parts of your body (metastatic), and who have received a prior trastuzumab-based regimen.

It is not known if ENHERTU is safe and effective in children.

Before you receive ENHERTU, tell your healthcare provider about all of your medical conditions, including if you:
- have lung or breathing problems.
- have signs or symptoms of an infection.
- have or have had any heart problems.
- are breastfeeding or plan to breastfeed. It is not known if ENHERTU passes into your breast milk. Do not breastfeed during treatment with ENHERTU and for 7 months after the last dose.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

How will I receive ENHERTU?

- You will receive ENHERTU into your vein through an intravenous (IV) line by your healthcare provider.
- ENHERTU is given 1 time every three weeks (21-day treatment cycle).
- Your healthcare provider will decide how many treatments you need.
- Your healthcare provider will give you medicines before your infusion to help prevent nausea and vomiting.
- Your healthcare provider may slow down or temporarily stop your infusion of ENHERTU if you have an infusion-related reaction, or permanently stop ENHERTU if you have severe infusion reactions.
- If you miss a planned dose of ENHERTU, call your healthcare provider right away to schedule an appointment. Do not wait until the next planned treatment cycle.

What are the possible side effects of ENHERTU?

ENHERTU can cause serious side effects. See “What is the most important information I should know about ENHERTU?”

The most common side effects of ENHERTU, when used in people with breast cancer, include:
- constipation
- low levels of blood potassium
- decreased appetite
- diarrhea
- pain in muscles and bones
- infections of the respiratory tract
- headache
- stomach-area (abdominal) pain

The most common side effects of ENHERTU, when used in people with stomach cancer, include:
- diarrhea
- low levels of blood potassium
- vomiting
- constipation
- fever
- hair loss

ENHERTU may cause fertility problems in males, which may affect the ability to father children. Talk to your healthcare provider if you have concerns about fertility.

These are not all of the possible side effects of ENHERTU. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

General information about the safe and effective use of ENHERTU.

Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. You can ask your pharmacist or healthcare provider for information about ENHERTU that is written for healthcare professionals.

What are the ingredients in ENHERTU?

Active Ingredient: fam-trastuzumab deruxtecan-nxki.

Inactive Ingredients: L-histidine, L-histidine hydrochloride monohydrate, polysorbate 80, and sucrose.

Manufactured by: Daiichi Sankyo, Inc., Basking Ridge, NJ 07920 U.S. License No. 2128
Marketed by: Daiichi Sankyo, Inc., Basking Ridge, NJ 07920 and AstraZeneca Pharmaceuticals LP, Wilmington, DE 19850

ENHERTU® is a registered trademark of Daiichi Sankyo Company, Ltd. © 2020 Daiichi Sankyo Co., Ltd. USMG-ENH-09-0522-003
For more information, call 1-877-437-7763 or go to https://www.ENHERTU.com

This Medication Guide has been approved by the U.S. Food and Drug Administration.

Revised: 05/2022